Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme - Contacts and Locations

Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

This study is ongoing, but not recruiting participants.

Study NCT00390403. Last updated on November 8, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00390403

Locations


United States, Alabama
	Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
	Birmingham, Alabama, United States, 35294

United States, Florida
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
	Tampa, Florida, United States, 33612-9497

United States, Georgia
	Winship Cancer Institute of Emory University
	Atlanta, Georgia, United States, 30322

United States, Maryland
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
	Baltimore, Maryland, United States, 21231-2410

United States, Michigan
	Josephine Ford Cancer Center at Henry Ford Hospital
	Detroit, Michigan, United States, 48202

United States, North Carolina
	Wake Forest University Comprehensive Cancer Center
	Winston-Salem, North Carolina, United States, 27157-1096

United States, Ohio
	Cleveland Clinic Taussig Cancer Center
	Cleveland, Ohio, United States, 44195

United States, Pennsylvania
	Abramson Cancer Center of the University of Pennsylvania
	Philadelphia, Pennsylvania, United States, 19104-4283

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators


Study Chair:	John Fiveash, MD	Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham